|
SKA2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 7.02659996854038E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.92130000020718E-07 |
| Normal-vs-Stage2 |
4.564000E-02 |
| Normal-vs-Stage3 |
1.11079999642882E-08 |
| Normal-vs-Stage4 |
5.26279020363063E-12 |
| Stage1-vs-Stage2 |
6.767800E-02 |
| Stage1-vs-Stage3 |
1.136620E-01 |
| Stage1-vs-Stage4 |
3.156500E-04 |
| Stage2-vs-Stage3 |
5.977000E-03 |
| Stage2-vs-Stage4 |
4.34959999999762E-05 |
| Stage3-vs-Stage4 |
7.426200E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.5279999487916E-10 |
| Normal-vs-AfricanAmerican |
3.162200E-02 |
| Normal-vs-Asian |
2.165900E-04 |
| Caucasian-vs-AfricanAmerican |
1.559250E-01 |
| Caucasian-vs-Asian |
1.398800E-01 |
| AfricanAmerican-vs-Asian |
7.543600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.17139999980631E-07 |
| Normal-vs-Female |
1.62929999492079E-08 |
| Male-vs-Female |
7.553600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.57810000001035E-06 |
| Normal-vs-Age(41-60Yrs) |
7.62279994681592E-09 |
| Normal-vs-Age(61-80Yrs) |
1.17340000005406E-06 |
| Normal-vs-Age(81-100Yrs) |
1.171920E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.496600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.015400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.762200E-02 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.982400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.413800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.965600E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.843700E-04 |
| Classical-VS-Follicular |
4.49540000000415E-05 |
| Classical-VS-Other |
9.172400E-01 |
| Classical-VS-Normal |
5.56839999665826E-08 |
| Tall-VS-Follicular |
4.06620004334002E-09 |
| Tall-VS-Other |
1.018190E-01 |
| Tall-VS-Normal |
1.95610194708706E-11 |
| Follicular-VS-Other |
1.587400E-01 |
| Follicular-VS-Normal |
2.119400E-01 |
| Other-VS-Normal |
9.103600E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.43319999995817E-06 |
| Normal-vs-N1 |
5.93390000025451E-07 |
| N0-vs-N1 |
7.062100E-02 |
|
|
